ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 0238 • ACR Convergence 2024

    Longitudinal Assessment of CD8+ T Cell Responses to SARS-CoV-2 Pre- and Post-breakthrough Infection and Its Association with COVID-19 Severity in Immunosuppressed Individuals

    Aljawharah Alrubayyi1, Aaron Shulkin1, Judith James2, Meggan Mackay3, Dinesh Khanna4, Amit Bar-Or5, Susan Macwana6, Ellen Goldmuntz7, James McNamara8, Sean McCarthy9, Matthew Sherman8, William Barry10, Ashley Pinckney11, Sarah Walker10, Sara Tedeschi12, Jeffrey Sparks13, Zachary Wallace14 and Gaurav Gaiha15, 1Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Feinstein Institutes for Medical Research, Manhasset, NY, 4University of Michigan, Ann Arbor, MI, 5University of Pennsylvania, Philadelphia, PA, 6Oklahoma Medical Research Foundation, Oklahoma City, 7NIAID/ NIH, Washington, DC, 8NIH, Bethesda, MD, 9DAIT/NIAID/NIH, Rockville, MD, 10Rho, Durham, NC, 11Rho, St Louis Park, NC, 12Brigham and Women's Hospital, Boston, MA, 13Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 14Massachusetts General Hospital, Newton, MA, 15Massachusetts General Hospital, Boston, MA

    Background/Purpose: Vaccines for SARS-CoV-2 have greatly reduced COVID-19 morbidity and mortality through the induction of neutralizing antibody responses. However, T cell responses are also induced…
  • Abstract Number: 0291 • ACR Convergence 2024

    Safety of Biologic Therapy in Kidney Transplant Recipients with Inflammatory Diseases: Real-world Experience from a Tertiary Medical Center

    Victoria Furer1, Omer Kersh2, Mark Berman3, Ayelet Grupper2 and Ori Elkayam4, 1Tel Aviv Medical Center, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv, Israel, 3Tel Aviv Sourasky Medical Center, Kefar sava, Israel, 4Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Management of solid-organ transplant (SOT) recipients with systemic inflammatory diseases represents a clinical challenge in the paucity of data related to the safety of…
  • Abstract Number: 1423 • ACR Convergence 2024

    An Observational Analytical Study on HCV Patients with Sicca Manifestations Before and After Direct-Acting Antivirals in Comparison with Sjogren’s Disease; Infection versus Autoimmunity

    Mohamed Tharwat Hegazy1, Amina Maher2, Tareq Algarf2, Manar Abdul-Aziz2, Osama Ashraf Wafa Mohamed3, Luca Quartuccio4, Naguib Zoheir2, Salvatore De Vita5 and Gaafar Ragab6, 1Faculty of Medicine, Cairo University, Cairo, Egypt, 2Cairo University, Cairo, Egypt, 3Newgiza University, Cairo, Egypt, 4Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, 5Udine University, Udine, Italy, 6Cairo University, Egypt, Cairo, Egypt

    Background/Purpose: Hepatitis C virus (HCV) is often associated with autoimmune features and extra-hepatic manifestations. Sicca symptoms are reported in about 30% of the cases. Both…
  • Abstract Number: 2611 • ACR Convergence 2024

    Continuation versus Temporary Interruption of Immunomodulatory Agents in Case of an Infection in IRD Patients: Results of a Randomized Controlled Trial

    Merel Opdam1, Nathan den Broeder2, Reinout van Crevel3, Lisa Schapink4, Léon Raijmakers4, Jasper Broen5, Lise Verhoef4 and Alfons den Broeder1, 1Sint Maartenskliniek, Ubbergen, Netherlands, 2Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, 3Radboudumc, Nijmegen, Netherlands, 4Sint Maartenskliniek, Nijmegen, Netherlands, 5Máxima Medical Centre, Eindhoven, Netherlands

    Background/Purpose: Immunomodulatory agents (IA) are widely used for the treatment of inflammatory rheumatic diseases (IRDs). Although IA are safe and effective, management of infections and infection…
  • Abstract Number: 0240 • ACR Convergence 2024

    Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

    Hilde S. Ørbo1, Asia-Sophia Wolf2, Taissa M. Kasahara3, Kristin H. Bjørlykke4, Ingrid Jyssum5, Joseph Sexton5, Anne Therese Tveter5, Guri Solum2, Ingrid Fadum Kjønstad2, Ingrid E. Christensen5, Tore K. Kvien6, Jørgen Jahnsen7, Espen A. Haavardsholm1, Ludvig A. Munthe8, Sella A. Provan5, John Torgils Vaage8, Kristin K. Jørgensen4, Gunnveig Grødeland8, Siri Mjaaland2, Silje W. Syversen9 and Guro L. Goll9, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 2Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, 3University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 4Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 7Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, 8Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
  • Abstract Number: 0304 • ACR Convergence 2024

    Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio

    doryan Garcia Olivas1, Judith Hernández Sánchez1, luis Bausá Gimeno1, Javier Nóvoa Medina1, Sergio Machín1, Maria Ángeles Acosta-Mérida1, Diana Botello-Corzo1, daniel Batista Perdomo1, José Ángel Hernández Beriain2 and Beatriz Tejera Segura1, 1Rheumatology Department. Hospital Universitario Insular de Gran Canaria, las Palmas, Spain, 2Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain

    Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of general infection due to the presence of comorbidities, underlying disease activity, and…
  • Abstract Number: 1483 • ACR Convergence 2024

    Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors

    SAUMYA TRIPATHY1, DEBASISH PANDIT2, Sarit Pattanaik3, Liza Rajasekhar4, VINEETA SHOBHA5, Chengappa Kavadichanda6, Ashish J Mathew7, Parasar Ghosh8, Ranjan Gupta9, Manish Rathi10, AVINASH JAIN11, MANOJ PARIDA12, Bidyut Das13 and Amita Aggarwal14, 1SCB Medical College, Cuttack, Odisha, India, Cuttack, Orissa, India, 2SJM MCH, Puri, Puri, Orissa, India, 3SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, Orissa, India, 4Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, 5ST JOHN'S MEDICAL COLLEGE, BENGALURU, Karnataka, India, 6Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, 7Christian Medical College, Vellore, Tamil Nadu, India, 8Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, 9All India Institute of Medical Sciences, New Delhi, Delhi, India, 10Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, 11SMS MCH, JAIPUR, JAIPUR, Rajasthan, India, 12SCB MEDICAL COLLEGE, CUTTACK, Cuttack, Orissa, India, 13SCB Medical College, Cuttack, Orissa, India, 14Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Infections in SLE are a major cause of morbidity and mortality. The susceptibility to infections in SLE is multifactorial. Immune dysregulation, immunosuppressive drug use and…
  • Abstract Number: 2612 • ACR Convergence 2024

    Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study

    Ana Cristina Medeiros-Ribeiro1, Joao de Oliveira2, Nadia Aikawa3, Sandra Pasoto2, Leonard Kupa2, Carla Goncalves Schahin Saad4, Luciana Parente2, ANA PAULA ASSAD2, Eduardo Borba2, Emily Figueiredo Neves Yuki2, Andrea Shimabuco4, Karina Bonfiglioli2, Diogo Domiciano2, Percival Sampaio-Barros4, Andre Franco2, Julio Moraes5, Murillo Dorio2, Claudia Goldenstein-Schainberg2, Henrique Carriço Da Silva2, Lucas Guimarães2, Fernanda Chaer6, Caio Laguna Reis de Carvalho2, Henrique Dalmolin2, Clovis Silva7 and Eloisa Bonfa2, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 3Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 5Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, 6Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Santos, Brazil, 7Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil

    Background/Purpose: Temporary methotrexate (MTX) discontinuation may enhance vaccine immune response, but there are no data for the recombinant zoster vaccine (RZV). This study assessed if…
  • Abstract Number: 0247 • ACR Convergence 2024

    Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study

    Sandra Pasoto1, Isabele Antonelli1, Ana Cristina Medeiros-Ribeiro2, Nadia Aikawa3, Leonard Kupa1, Eduardo Borba1, Luciana Seguro4, Emily Figueiredo Neves Yuki1, ANA PAULA ASSAD1, Carla Saad4, Andrea Shimabuco4, Andrea Negrini1, Julia Medeiros1, Talita Ribeiro1, Samuel Shinjo4, Percival Sampaio-Barros4, Danieli Andrade5, Fernando Souza4, Renata Miossi4, Clovis Silva6 and Eloisa Bonfa1, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, 3Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 5University of São Paulo, São Paulo, SP, Brazil, 6Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil

    Background/Purpose: Recently, it was demonstrated that temporarily halting mycophenolate mofetil (MMF) for 1-week post-COVID-19 vaccination in systemic lupus erythematosus (SLE) patients improved humoral response, without…
  • Abstract Number: 0414 • ACR Convergence 2024

    Relationship Between Culture Negative Infectious Osteomyelitis and Chronic Nonbacterial Osteomyelitis

    Andrew Grim1, Yongdong (Dan) Zhao2, Christine Wang1, Erin Janssen3, Jessica Turnier4, Anastasia Hyrhorczuk1 and Nadine Saad1, 1University of Michigan, Ann Arbor, MI, 2University of Washington, Redmond, WA, 3CS Mott Children's Hospital, Ann Arbor, MI, 4University of Michigan, Saline, MI

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder. Some patients with CNO may present acutely and be misdiagnosed as infectious osteomyelitis (IO).…
  • Abstract Number: 1509 • ACR Convergence 2024

    Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort

    Rosana Quintana1, Guillermo Pons-Estel2, Karen Roberts3, Erika S. Palacios Santillan3, Íñigo Rúa-Figueroa4, José María Pego-Reigosa5, Pablo Ibañez6, Leonel Ariel Berbotto7, Maria Constanza Bertolaccini8, Marina Laura Micelli9, Cecilia Pisoni10, Vitalina De Souza Barbosa11, Henrique de Ataíde Mariz12, Francinne Machado Ribeiro13, Luciana Parente14, Emília Sato15, Milena Mimica Davet16, Gustavo Aroca Martínez17, Fabio Bonilla-Abadía18, Gerardo Quintana López19, Reyna E. Sánchez Briones20, Mario Pérez Cristóbal21, Luis H. Silveira Torre22, Ignacio García De La Torre23, Ivan Morales Avendaño24, Pablo Gamez-Siller25, Astrid Paats26, Jorge N. Cieza Calderón27, Andy Armando Mendoza Maldonado28, Martin Rebella29, Gonzalo Silveira30, John Fredy Jaramillo31, Monica Sanchez32, Urbano Sbarigia33, Ashley Orillion34, Federico Zazzetti35, Graciela Alarcon36 and Bernardo Pons-Estel37, and Grupo Latino Americano de Estudio del Lupus (GLADEL), 1Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, 3Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, 5Galicia Health Service (SERGAS), Vigo, Spain, 6Servicio de Reumatología del HIGA San Martín, La Planta, Argentina, 7Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, 8Servicio de Reumatologia - Hospital Angel C. Padilla, San Miguel de Tucumán, Argentina, 9Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, 10CEMIC, Buenos Aires, Argentina, 11Hospital das Clínicas, Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, 12Universidad Federal de Pernambuco, Recife, Brazil, 13Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, 14Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 15Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, 16Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, 17Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, 18Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, 19Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, 20División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, 21Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, 22Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 23Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, 24Hospital Central Dr. Ignacio Morones Prieto, Potosi, Mexico, 25Servicio de Reumatologia del Hospital Universitario, "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 26Hospital de Clínicas I, Asunción, Paraguay, 27Hospital Nacional Edgardo Rebagliatti Martins, Lima, Perú, Lima, Peru, 28Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 29Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, 30Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, 31Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, 32Unidad Nefrologia,Hospital fernandez, CABA, Argentina, 33Johnson & Johnson Innovative Medicine, Brussels, Belgium, 34Johnson & Johnson Innovative Medicine, Spring House, PA, PA, 35Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 36The University of Alabama at Birmingham, Oakland, CA, 37Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of serious infections, which in turn, are associated with morbidity and mortality. The Systemic…
  • Abstract Number: 2613 • ACR Convergence 2024

    Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study

    Gregory McDermott1, Ritu Gill2, Suzanne Byrne3, Staci Gagne3, Emily Kowalski3, Xiaosong Wang4, Grace Qian4, Katarina Bade3, Kevin Mueller3, Alene Saavedra3, Kathleen Vanni4, Caleb Bolden5, Naomi Patel5, Krishan Guzzo3, Marcy Bolster5, Shruthi Srivatsan5, Pierre-Antoine Juge6, Tracy J Doyle7, Zachary Wallace8 and Jeffrey Sparks9, 1Brigham and Women's Hospital, Brookline, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women’s Hospital, Boston, MA, 5Massachusetts General Hospital, Boston, MA, 6Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, 7Brigham and Women's Hospital, West Roxbury, MA, 8Massachusetts General Hospital, Newton, MA, 9Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: RA is associated with several forms of parenchymal lung disease, including interstitial lung disease (ILD), bronchiectasis, and emphysema. Acute COVID-19 and other respiratory viruses…
  • Abstract Number: 0248 • ACR Convergence 2024

    Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study

    Nadia Aikawa1, Ana Cristina Medeiros-Ribeiro2, Sandra Pasoto3, Leonard Kupa3, Luciana Seguro4, ANA PAULA ASSAD3, Eduardo Borba3, Carla Goncalves Schahin Saad4, Emily Figueiredo Neves Yuki3, Danieli Andrade5, Andrea Shimabuco4, Karina Bonfiglioli3, Diogo Domiciano3, Julio Moraes3, Samuel Shinjo4, Percival Sampaio-Barros4, Henrique Giardini3, Joao de Oliveira3, Isabele Antonelli3, Renata Pinheiro3, Thais Bonini3, Marta Lopes6, Clovis Silva7 and Eloisa Bonfa3, 1Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 5University of São Paulo, São Paulo, SP, Brazil, 6Infectious Disease Department, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 7Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil

    Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are at high risk of herpes zoster (HZ) due to their condition and treatment. The new recombinant vaccine…
  • Abstract Number: 0513 • ACR Convergence 2024

    Effects of Cumulative Rituximab Exposure in Patients with Rheumatoid Arthritis: Results from Cohort at a Tertiary Academic Health Care Setting

    Ioasaf Karafotias1, Maryam Adas1, Katie Bechman1, Nicholas Williamson1, Mark Hughes1, Daksh Mehta2, Ritika Roy1, Sam Norton3 and James Galloway4, 1King's College London, London, United Kingdom, 2King's College Hospital, London, United Kingdom, 3King's College London, London, England, United Kingdom, 4Centre for Rheumatic Diseases, King's College London, London, United Kingdom

    Background/Purpose:  Rituximab targets CD20-positive B cells and is used to treat rheumatoid arthritis (RA). B cell depletion may result in hypogammaglobulinemia. Hypogammaglobulinemia is a risk…
  • Abstract Number: 1519 • ACR Convergence 2024

    Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus

    Chunhui Chen1, Emily Wu2, Huong Do3 and Kyriakos Kirou3, 1New York Presbyterian Queens, Flushing, NY, 2Hospital for Special Surgery, Rochester, NY, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: Lymphopenia is common in patients with systemic lupus erythematosus (SLE), occurring in 75-90% of cases over the disease course. It can result from SLE…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology